Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Bronchiolitis Obliterans Syndrome 1

Interventions

pembrolizumab 45Carboplatin 40Cisplatin 36Paclitaxel 29Pemetrexed 24Nivolumab 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Fluorouracil 14Capecitabine 14atezolizumab 13Docetaxel 13trastuzumab deruxtecan 12durvalumab 12Trastuzumab 12Lenalidomide 12daratumumab 11Cytarabine 11olaparib 10Prednisone 10Bortezomib 10Bevacizumab 10130-nm albumin-bound paclitaxel 10Doxorubicin 9venetoclax 8Oxaliplatin 8Crizotinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Has announcements × KD025 × Clear all
NCT03640481 2024-12-12

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Sanofi

Phase 2 Terminated
159 enrolled 25 charts 1 FDA

Bronchiolitis Obliterans Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡